Innovative Therapies to Combat Multiple Sclerosis

Harnessing the Power of Antigen-Specific Dendritic Cells for Immune Regulation

1
People with multiple sclerosis in Spain
1
People suffering from this disease in Europe
1
People with multiple sclerosis in the world

What is Multiple Sclerosis?

Multiple sclerosis is an autoimmune disease in which the immune system attacks myelin, the substance that covers nerve fibers in the brain and spinal cord. Myelin acts as an insulator, allowing nerve impulses to travel quickly along nerve fibers. When myelin is damaged, nerve impulses can be interrupted or stopped, leading to a wide range of neurological symptoms.

In Europe only there are, around 500,000 people suffering from this disease, which is often diagnosed in individuals (mostly women) aged 20 to 40.

We’re in dire need of novel treatments for Multiple Sclerosis that not only effectively address the root cause of the disease but also offer safety and efficiency. These therapies should aim to minimize treatment duration and frequency while mitigating potential side effects.

Multiple sclerosis is

Heterogeneous

It is also called “the disease of 1000 faces.”

Neurological.

Nerve impulse transmission fails

Various symptoms.

Mobility, sensory, vision, fatigue, etc. problems.

Unpredictable

Its course cannot be predicted with certainty and may worsen over time.

There is no known cause or cure.

Research and your support are essential

It appears in young adults.

First cause of non-traumatic disability in this group.

But… Why does Multiple Sclerosis occur?

The cause of MS is unknown, but researchers believe it results from a combination of genetic and environmental factors that cause our immune system cells to attack the nervous system. The immune system’s mission is to defend our bodies against external threats such as viruses and bacteria. However, in autoimmune diseases like MS, our defenses attack the body itself, making the immune system the aggressor: it attacks us instead of protecting us.

Although, as already explained, the cause may be a combination of environmental and genetic factors, MS is not considered a hereditary disease. However, there is a genetic susceptibility, meaning we are at a higher risk of developing MS if a family member has the disease.

Our Goal with this project

To take tolerogenic dendritic cell-based therapies to the next level

To fast-track cell development of a 2nd generation VitD3DC product for clinical application

Latest news and press releases

Sign up to our newsletter and be the first to know our progress and results

Fill out this field
Please enter a valid email address.